Reference
Xu H, et al. EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors. Frontiers in Pharmacology 13: 976731, 16 Sep 2022. Available from: URL: http://www.frontiersin.org/Pharmacology
Rights and permissions
About this article
Cite this article
Afatinib. Reactions Weekly 1934, 19 (2022). https://doi.org/10.1007/s40278-022-28400-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-28400-3